Novavax Inc. (NASDAQ: NVAX) appointed Dr. Robert Walker as executive vice president and head of research and development, the company announced March 30. Walker previously served as chief medical officer at the vaccine company since joining in 2022.

Walker brings more than 30 years of experience in drug and vaccine development across private and public sectors. He previously held the chief medical officer position at the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services.

In his new role, Walker will oversee preclinical and clinical research and development functions. The company stated his focus will include data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the company's pipeline.

"Bob has demonstrated deep scientific expertise, strong leadership and an unwavering commitment to advancing Novavax's technology platform," said John C. Jacobs, president and chief executive officer of Novavax.

Walker succeeds Dr. Ruxandra Draghia-Akli, who departed the company to pursue other opportunities.

Walker earned his medical degree from the University of Maryland and completed internal medicine training at The George Washington University. He completed his fellowship in pulmonary and critical care medicine at the University of Pennsylvania.

The information is based on a company press release.